NEW YORK GENOME CENTER INC

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2010

Legal Domicile

Principal Officer

TOM MANIATIS

Phone

6469777000

Tax Period

2023-01-01 to 2023-12-31

NEW YORK GENOME CENTER INC, founded in 2010, is a mid-sized nonprofit in the Health Care sector that reported $92.9M in total revenue in fiscal year 2023. Revenue surged 37% from the prior year, signaling strong growth momentum. Expenses of $81.9M left a modest 12% surplus.

Mission

OPERATE A STATE-OF-THE-ART, WORLD CLASS GENOMIC RESEARCH CENTER THAT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O.

Program Service Accomplishments

Program 1

Expenses: $58,296,070 Revenue: $4,514,112

GENOME SEQUENCING: NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST TEN YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 102,800 WHOLE GENOME...

GENOME SEQUENCING: NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST TEN YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 102,800 WHOLE GENOME SAMPLES. NYGC HAS ACQUIRED TWO OF THE NEWEST ILLUMINA NOVASEQ X SYSTEMS SEQUENCERS, EACH WITH THE CAPACITY TO SEQUENCE TWENTY THOUSAND HUMAN GENOMES ANNUALLY. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. IN ADDITION, NYGC OPERATES AN OXFORD NANOPORE PROMETHION SEQUENCER FOR LONG READ SEQUENCING, AND CONTINUED TO TEST AND VALIDATE A HIGH-THROUGHPUT SEQUENCER FROM ULTIMA GENOMICS (THE UG100). SEE SCHEDULE O.

Program 2

Expenses: $7,058,489 Revenue: $5,198,422

CLINICAL SEQUENCING: NYGC IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS THROUGH ITS CLEP/CLIA CERTIFIED CLINICAL LABORATORY: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLEGENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE GENOME AND TRANSCRIPTOME SEQUENCING, CONSTITUTIONAL WHOLE EXOME SEQUENCING, TARGETED VARIANT TESTING USING SANGER SEQUENCING, ONCOLOGY WHOLE EXOME AND TRANSCRIPTOME SEQUENCING, AND THE SMASH GENOMIC ASSAY.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $81,695,780

Program Service Revenue $9,712,534

Investment Income $191,646

Other Revenue $1,340,469

TOTAL REVENUE $92,940,429

Expense Breakdown

Grants Paid $3,387,586

Salaries & Benefits $33,690,192

Fundraising Expenses $1,355,909

Program Expenses $65,354,559

Other Expenses $44,780,821

TOTAL EXPENSES $81,872,824

Year-over-Year Comparison

	2023	2022	Change
Revenue	$92,940,429	$67,901,686	+0.4%
Expenses	$81,872,824	$72,195,873	+0.1%
Net Income	$11,067,605	$-4,294,187	-3.6%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✓ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

224

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✓ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$1,605,563

Total Directors

$659,380

Key Employees

$2,763,757

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
RUSSELL L CARSON MBA	DIRECTOR & CHAIRMAN	1.00	Officer Director	$0	$0	$0
IVAN G SEIDENBERG MBA	DIRECTOR & CO-CHAIR	1.00	Officer Director	$0	$0	$0
HERB PARDES MD	DIRECTOR & EXEC. VICE CHAI	1.00	Director	$0	$0	$0
GORDON F TOMASELLI MD	DIRECTOR	1.00	Director	$0	$0	$0
BRUCE STILLMAN PHD	DIRECTOR	1.00	Director	$0	$0	$0
KATRINA ARMSTRONG MD	DIRECTOR	1.00	Director	$0	$0	$0
SELWYN VICKERS MD	DIRECTOR	1.00	Director	$0	$0	$0
DENNIS S CHARNEY MD	DIRECTOR	1.00	Director	$0	$0	$0
DAFNA BAR-SAGI PHD	DIRECTOR	1.00	Director	$0	$0	$0
KEVIN J TRACEY MD	DIRECTOR	1.00	Director	$0	$0	$0
KENNETH A DILL PHD	DIRECTOR	1.00	Director	$0	$0	$0
RICHARD P LIFTON MD PHD	DIRECTOR	1.00	Director	$0	$0	$0
ROBERT HARRINGTON MD	DIRECTOR (AS OF 10/23)	1.00	Director	$0	$0	$0
FRANCIS LEE MD PHD	DIRECTOR (3/23 TO 10/23)	1.00	Director	$0	$0	$0
AUGUSTINE M K CHOI MD	DIRECTOR (THRU 3/23)	1.00	Director	$0	$0	$0
ELI CASDIN	DIRECTOR	1.00	Director	$0	$0	$0
NICHOLAS DONOFRIO	DIRECTOR	1.00	Director	$0	$0	$0
JOSEPH E EDELMAN	DIRECTOR	1.00	Director	$0	$0	$0
JOHN B EHRENKRANZ	DIRECTOR	1.00	Director	$0	$0	$0
ANTHONY B EVNIN PHD	DIRECTOR	1.00	Director	$0	$0	$0
JOHN P HAVENS	DIRECTOR	1.00	Director	$0	$0	$0
WESLIE R JANEWAY	DIRECTOR	1.00	Director	$0	$0	$0
FRANK V SICA	DIRECTOR & COMMITTEE CHAIR	1.00	Director	$0	$0	$0
JIM SIMONS PHD	DIRECTOR	1.00	Director	$0	$0	$0
NANCY THORNBERRY	DIRECTOR	1.00	Director	$0	$0	$0
TOM MANIATIS PHD	SCIENTIFIC DIRECTOR & CEO	40.00	Officer Director	$659,380	$0	$659,380
ELIZABETH BROOKS O'BRIEN	VP & GENERAL COUNSEL	40.00	Officer	$466,101	$44,808	$510,909
MARIA JOANTA	CHIEF FINANCIAL OFFICER	40.00	Officer	$385,336	$49,938	$435,274
CAROL ASHE	CHIEF BUSINESS OFFICER	40.00	Key Emp	$436,587	$19,917	$456,504
CHARLES GAGNON	CHIEF INFORMATION OFFICER	40.00	Key Emp	$344,112	$49,131	$393,243
THOMAS LEHNER	SCI DIR, NEURO DIS GEN	40.00	Key Emp	$404,554	$33,760	$438,314
SOREN GERMER	SVP, GENOME TECHNOLOGIES	40.00	Key Emp	$437,568	$37,446	$475,014
MICHAEL CHARLES ZODY	SCIENTIFIC DIR, COMP BIOLO	40.00	Key Emp	$369,902	$29,110	$399,012
SARAH LESSER AVINS	SVP, ADVANCEMENT & CHIEF D	40.00	Key Emp	$564,596	$37,074	$601,670
SHAILAJA GARGEYA	SENIOR DIR, SOFTWARE ENGIN	40.00	Highest	$332,688	$19,917	$352,605
DAYNA M OSCHWALD	CHIEF OF STAFF	40.00	Highest	$282,476	$33,972	$316,448
CHRISTOPHER PHIFER BLACK	SENIOR DIRECTOR, RESEARCH	40.00	Highest	$255,308	$44,331	$299,639
HANNAH GOULDING	SENIOR DIRECTOR, HUMAN RES	40.00	Highest	$245,119	$14,824	$259,943
CATHERINE E REEVES	SENIOR DIRECTOR, RESEARCH	40.00	Highest	$243,210	$32,796	$276,006

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$92,940,429	$81,872,824	$184,052,230	$11,067,605
2022	$67,901,686	$72,195,873	$181,740,451	$-4,294,187
2021	$72,299,111	$69,108,421	$85,222,125	$3,190,690
2020	$60,783,989	$72,306,280	$83,547,232	$-11,522,291
2019	$42,244,445	$80,199,768	$97,126,046	$-37,955,323
2018	$128,448,950	$84,558,185	$148,772,470	$43,890,765